InvestorsHub Logo
Followers 64
Posts 24150
Boards Moderated 0
Alias Born 11/23/2016

Re: None

Sunday, 02/19/2017 2:05:26 PM

Sunday, February 19, 2017 2:05:26 PM

Post# of 466572
"Celgene Corporation (CELG) today announced that its phase III SUNBEAM trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis (RMS), met the primary endpoint in reducing annualized relapse rate (ARR), compared to weekly interferon (IFN) ß-1a (Avonex®)."

http://finance.yahoo.com/news/celgene-announces-positive-results-phase-123000513.html?soc_src=social-sh&soc_trk=ma


Guess more incentive for Biogen to partner with Anavex if successful in testing A2-73.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News